Latest stories on NVCR
NovoCure: Why I'm Fading The Q2 Earnings Rally
Seeking Alpha48 · neutralanalyst
NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)
Seeking Alpha71 · bullishearnings
NovoCure Limited 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Why Did CSX, UNP, NVCR Stocks Surge To 52-Week Highs Today?
Stocktwits News67 · bullishgeneral
NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally?
Stocktwits News73 · bullishearnings
Novocure outlines 2026 revenue of $710M-$725M while targeting adjusted EBITDA of $0M-$15M
Seeking Alpha67 · bullishearnings
NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Novocure Reports Record Second-Quarter Revenue as Optune Expansion Drives Higher 2026 Outlook
InvestorsHub73 · bullishearnings
Novocure Reports Record Second-Quarter Revenue as Optune Expansion Drives Higher 2026 Outlook
Yahoo Finance73 · bullishearnings
Novocure Flashes A Bullish Signal As It Breaks Out; Have Shares 'Turned A Corner?'
Investors.com58 · neutralgeneral
Novocure Achieves Record Revenues and Patient Growth, Raises 2026 Guidance on Strong Optune Pax Launch
July 23, 2026
MarketChameleon73 · bullishearnings
NovoCure surges on guidance raise, Q2 beats
Seeking Alpha73 · bullishearnings
Novocure's Record Quarter: Patient Growth and Margin Expansion Highlight Positive Momentum
July 23, 2026
MarketChameleon73 · bullishearnings
NovoCure GAAP EPS of -$0.13 beats by $0.20, revenue of $183.6M beats by $11.16M
Seeking Alpha68 · bullishearnings
NovoCure Ltd (NVCR) files 8-K
SEC 8-K50 · neutralgeneral
Novocure Reports Second Quarter 2026 Financial Results | NVCR Stock News
StockTitan50 · neutralearnings
NovoCure Q2 2026 Earnings Preview
Seeking Alpha50 · neutralearnings
NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026
Seeking Alpha42 · neutralearnings
Big movers after the closing bell: COST, NVCR, PNW
Seeking Alpha47 · neutralgeneral
Novocure to Report Second Quarter 2026 Financial Results | NVCR Stock News
StockTitan50 · neutralgeneral
Novocure’s Optune Pax Secures CE Mark for Pancreatic Cancer
TipRanks73 · bullishproduct/pr
NovoCure Ltd (NVCR) files 8-K
SEC 8-K50 · neutralgeneral
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer | NVCR Stock News
StockTitan73 · bullishproduct/pr
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
The Motley Fool56 · neutralanalyst
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
The Motley Fool56 · neutralanalyst